Form 4: Dermata Therapeutics Director Buys Shares

Dermata Therapeutics Director Kathleen D. Scott acquired 11 shares of common stock for $1.19 per share.

Summary

• Kathleen D. Scott, a Director at Dermata Therapeutics, Inc., purchased 11 shares of common stock on June 16, 2026.
• The transaction was executed at a price of $1.19 per share.
• Following this transaction, Ms. Scott directly owns 11 shares of common stock.
• Additionally, she beneficially owns 1 share indirectly through the Scott 2008 Trust.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive filing due to the director's direct investment, signaling confidence, though the small number of shares limits its overall market impact.

Positives

• Director's personal investment in the company's stock, indicating confidence in the company's future prospects.
• The purchase price of $1.19 per share suggests a potentially attractive entry point for the director.

Future Outlook

No specific forward-looking statements or guidance were provided in this filing.

Industry Context

StockSavvy.ai notes that insider purchases, particularly by directors, can be interpreted as a positive signal to the market, suggesting management's belief in the company's intrinsic value and future growth potential, especially in the biotechnology sector where such investments can be significant.

Stakeholder Impact

• Shareholders may view the director's purchase as a positive indicator of confidence in the company's future performance.
• The transaction has minimal direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Dermata Therapeutics, DRMA, Form 4, Insider Trading, Director Purchase, Common Stock, Beneficial Ownership